Clinical Trial Results:
A prospective single-arm, monocentric, phase-II explorative study on evaluation of diagnostic use of the PET tracer (18F)-florbetaben (Neuraceq®) in patient with patient with suspected cardiac amyloidosis
Summary
|
|
EudraCT number |
2015-005384-16 |
Trial protocol |
IT |
Global end of trial date |
23 Feb 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
26 May 2022
|
First version publication date |
26 May 2022
|
Other versions |
|
Summary report(s) |
Floramicar Summary |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
FLORAMICAR
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Fondazione Toscana Gabriele Monasterio
|
||
Sponsor organisation address |
via trieste , pisa, Italy,
|
||
Public contact |
U.O.C Farmaceutica Ospedaliera, Fondazione Toscana Gabriele Monasterio, +39 0585493507, farmacisti@ftgm.it
|
||
Scientific contact |
U.O.C Farmaceutica Ospedaliera, Fondazione Toscana Gabriele Monasterio, +39 0585493507, farmacisti@ftgm.it
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 Jul 2020
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
23 Feb 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Establish the affinity of the tracer [18F] -Florbetaben for amyloid deposits in patients with clinican suspition of cardiac amyloidosis AL and ATTR.
|
||
Protection of trial subjects |
Study protocol was conformed to the 1975 Declaration of Helsinki. It was approved by the institutional ethics committee and by the Agenzia Italiana del Farmaco committee; all patients provided written informed consent.
|
||
Background therapy |
na | ||
Evidence for comparator |
na | ||
Actual start date of recruitment |
23 Jun 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Italy: 12
|
||
Worldwide total number of subjects |
12
|
||
EEA total number of subjects |
12
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
10
|
||
From 65 to 84 years |
2
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
Age>20 years, high clinical suspicion of cardiac amyloidosis based on cardiac examination, biomarkers (Nt-proBNP, HS-TnT, immunoglobulin light chains in serum and urine, plasma protein electrophoresis and serum free light chains), baseline ECG, baseline echocardiography, cardiac MRI, histological evidence of amyloid (Congo red stain). | ||||||
Pre-assignment
|
|||||||
Screening details |
Age>20 years, high clinical suspicion of cardiac amyloidosis based on cardiac examination, biomarkers (Nt-proBNP, HS-TnT, immunoglobulin light chains in serum and urine, plasma protein electrophoresis and serum free light chains), baseline ECG, baseline echocardiography, cardiac MRI, histological evidence of amyloid (Congo red stain). | ||||||
Period 1
|
|||||||
Period 1 title |
[18F]-Florbetaben PET/CT (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
na
|
||||||
Arms
|
|||||||
Arm title
|
Patient with CA | ||||||
Arm description |
Patient with CA | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
florbetaben
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Injection
|
||||||
Routes of administration |
Solution for injection
|
||||||
Dosage and administration details |
infusion of 300 MBq/ml of [18F]-Florbetaben followed by a saline flush of 10 ml (1 ml/s)
|
||||||
|
|
||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||
Reporting group title |
[18F]-Florbetaben PET/CT
|
|||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||
Subject analysis set title |
18-85
|
|||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||
Subject analysis set description |
Patients with ATTR, compared with those with AL and non-CA, were older and presented with higher left atrial volume and
left ventricular mass index (23.5 4.5 ml/m2; p ¼ 0.003 vs. non-CA; and 129 39 g/m2; p ¼ 0.003 vs. non-CA, respectively). Furthermore, whereas patients with CA presented with worse diastolic dysfunction, no difference could be observed in terms of left ventricular systolic function when patients with CA were compared with patients with non-CA.
CARDIAC PET/CT CHARACTERISTICS. Static images qualitative analysis. A total of 240 static cardiac scans (4 scans per patient: early; intermediate; late; and delayed) were evaluated by 2 independent observers. Images indicated a significant radiotracer myocardial uptake in 121 of 240 scans (50%).
|
|||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Patient with CA
|
||
Reporting group description |
Patient with CA | ||
Subject analysis set title |
18-85
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Patients with ATTR, compared with those with AL and non-CA, were older and presented with higher left atrial volume and
left ventricular mass index (23.5 4.5 ml/m2; p ¼ 0.003 vs. non-CA; and 129 39 g/m2; p ¼ 0.003 vs. non-CA, respectively). Furthermore, whereas patients with CA presented with worse diastolic dysfunction, no difference could be observed in terms of left ventricular systolic function when patients with CA were compared with patients with non-CA.
CARDIAC PET/CT CHARACTERISTICS. Static images qualitative analysis. A total of 240 static cardiac scans (4 scans per patient: early; intermediate; late; and delayed) were evaluated by 2 independent observers. Images indicated a significant radiotracer myocardial uptake in 121 of 240 scans (50%).
|
|
||||||||||
End point title |
CA | |||||||||
End point description |
||||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
only one acquisition
|
|||||||||
|
||||||||||
Attachments |
results |
|||||||||
Statistical analysis title |
results | |||||||||
Comparison groups |
Patient with CA v 18-85
|
|||||||||
Number of subjects included in analysis |
24
|
|||||||||
Analysis specification |
Post-hoc
|
|||||||||
Analysis type |
other | |||||||||
P-value |
< 0.001 | |||||||||
Method |
Chi-squared | |||||||||
Confidence interval |
|
|||||||||||
Adverse events information [1]
|
|||||||||||
Timeframe for reporting adverse events |
all study
|
||||||||||
Assessment type |
Systematic | ||||||||||
Dictionary used for adverse event reporting
|
|||||||||||
Dictionary name |
MedDRA | ||||||||||
Dictionary version |
24.1
|
||||||||||
Reporting groups
|
|||||||||||
Reporting group title |
all patients
|
||||||||||
Reporting group description |
- | ||||||||||
|
|||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||
|
|||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: NO SAE OR AE REGISTERED DURING THE STUDY |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |